|
1
|
Pellegriti G, Frasca F, Regalbuto C,
Squatrito S and Vigneri R: Worldwide increasing incidence of
thyroid cancer: Update on epidemiology and risk factors. J Cancer
Epidemiol. 2013:9652122013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kim J, Gosnell JE and Roman SA: Geographic
influences in the global rise of thyroid cancer. Nat Rev
Endocrinol. 16:17–29. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rahib L, Smith BD, Aizenberg R, Rosenzweig
AB, Fleshman JM and Matrisian LM: Projecting cancer incidence and
deaths to 2030: The unexpected burden of thyroid, liver, and
pancreas cancers in the United States. Cancer Res. 74:2913–2921.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang J, Yu F, Shang Y, Ping Z and Liu L:
Thyroid cancer: Incidence and mortality trends in China, 2005–2015.
Endocrine. 68:163–173. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sherman SI: Thyroid carcinoma. Lancet.
361:501–511. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Burns WR and Zeiger MA: Differentiated
thyroid cancer. Semin Oncol. 37:557–566. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rahmani N, Abbas Hashemi S, Fazli M and
Raisian M: Clinical management and outcomes of papillary,
follicular and medullary thyroid cancer surgery. Med Glas.
10:164–167. 2013.PubMed/NCBI
|
|
9
|
Grant CS: Papillary thyroid cancer:
Strategies for optimal individualized surgical management. Clin
Ther. 36:1117–1126. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Manoj G, Deepika K, Ryoko O, Saket J,
Vikas M and Wenwen C: Laminin-5γ-2 (LAMC2) is highly expressed in
anaplastic thyroid carcinoma and is associated with tumor
progression, migration, and invasion by modulating signaling of
EGFR. J Clin Endocrinol Metab. 99:E62–E72. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu H, Sun Y, Ye H, Yang S, Lee SL and de
las Morenas A: Anaplastic thyroid cancer: Outcome and the
mutation/expression profiles of potential targets. Pathol Oncol
Res. 21:695–701. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ernani V, Kumar M, Chen AY and Owonikoko
TK: Systemic treatment and management approaches for medullary
thyroid cancer. Cancer Treat Rev. 50:89–98. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hulpiau P and van Roy F: Molecular
evolution of the cadherin superfamily. Int J Biochem Cell Biol.
41:349–369. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Casal JI and Bartolomé RA: Beyond
N-Cadherin, Relevance of Cadherins 5, 6 and 17 in Cancer
Progression and Metastasis. Int J Mol Sci. 20:33732019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Thomson RB, Ward DC, Quaggin SE, Igarashi
P, Muckler ZE and Aronson PS: cDNA cloning and chromosomal
localization of the human and mouse isoforms of Ksp-cadherin.
Genomics. 51:445–451. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Thedieck C, Kuczyk M, Klingel K, Steiert
I, Müller CA and Klein G: Expression of Ksp-cadherin during kidney
development and in renal cell carcinoma. Br J Cancer. 92:2010–2017.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Calì G, Zannini M, Rubini P, Tacchetti C,
D'Andrea B, Affuso A, Wintermantel T, Boussadia O, Terracciano D,
Silberschmidt D, et al: Conditional inactivation of the E-cadherin
gene in thyroid follicular cells affects gland development but does
not impair junction formation. Endocrinology. 148:2737–2746. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Koumarianou P, Goméz-López G and
Santisteban P: Pax8 controls thyroid follicular polarity through
cadherin-16. J Cell Sci. 130:219–231. 2017.PubMed/NCBI
|
|
19
|
de Cristofaro T, Di Palma T, Fichera I,
Lucci V, Parrillo L, De Felice M and Zannini M: An essential role
for Pax8 in the transcriptional regulation of cadherin-16 in
thyroid cells. Mol Endocrinol. 26:67–78. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Calì G, Gentile F, Mogavero S, Pallante P,
Nitsch R, Ciancia G, Ferraro A, Fusco A and Nitsch L:
CDH16/Ksp-cadherin is expressed in the developing thyroid gland and
is strongly down-regulated in thyroid carcinomas. Endocrinology.
153:522–534. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li P, Wu Q, Sun Y, Pan X, Han Y, Ye B,
Zhang Y, Dong J and Zheng Z: Downregulation of cdh16 in papillary
thyroid cancer and its potential molecular mechanism analysed by
qRT-PCR, TCGA and in silico analysis. Cancer Manag Res.
11:10719–10729. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rhodes DR, Kalyana-Sundaram S, Mahavisno
V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ,
Kincead-Beal C, Kulkarni P, et al: Oncomine 3.0: Genes, pathways,
and networks in a collection of 18,000 cancer gene expression
profiles. Neoplasia. 9:166–180. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
He H, Jazdzewski K, Li W, Liyanarachchi S,
Nagy R, Volinia S, Calin GA, Liu CG, Franssila K, Suster S, et al:
The role of microRNA genes in papillary thyroid carcinoma. Proc
Natl Acad Sci USA. 102:19075–19080. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vasko V, Espinosa AV, Scouten W, He H,
Auer H, Liyanarachchi S, Larin A, Savchenko V, Francis GL, de la
Chapelle A, et al: Gene expression and functional evidence of
epithelial-to-mesenchymal transition in papillary thyroid carcinoma
invasion. Proc Natl Acad Sci USA. 104:2803–2808. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Giordano TJ, Au AYM, Kuick R, Thomas DG,
Rhodes DR, Wilhelm KG Jr, Vinco M, Misek DE, Sanders D, Zhu Z, et
al: Delineation, functional validation, and bioinformatic
evaluation of gene expression in thyroid follicular carcinomas with
the PAX8-PPARG translocation. Clin Cancer Res. 12:1983–1993. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vasaikar SV, Straub P, Wang J and Zhang B:
LinkedOmics: Analyzing multi-omics data within and across 32 cancer
types. Nucleic Acids Res. 46D:D956–D963. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang X, Liu G, Li W, Zang L, Li D, Wang Q,
Yu F and Xiang X: Silencing of zinc finger protein 703 inhibits
medullary thyroid carcinoma cell proliferation in vitro and
in vivo. Oncol Lett. 19:943–951. 2020.PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Suzuki ST: Structural and functional
diversity of cadherin superfamily: Are new members of cadherin
superfamily involved in signal transduction pathway? J Cell
Biochem. 61:531–542. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Vleminckx K, Vakaet L Jr, Mareel M, Fiers
W and van Roy F: Genetic manipulation of E-cadherin expression by
epithelial tumor cells reveals an invasion suppressor role. Cell.
66:107–119. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Perl AK, Wilgenbus P, Dahl U, Semb H and
Christofori G: A causal role for E-cadherin in the transition from
adenoma to carcinoma. Nature. 392:190–193. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shiozaki H, Oka H, Inoue M, Tamura S and
Monden M: E-cadherin mediated adhesion system in cancer cells.
Cancer. 77 (Suppl):1605–1613. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pal M, Bhattacharya S, Kalyan G and Hazra
S: Cadherin profiling for therapeutic interventions in Epithelial
Mesenchymal Transition (EMT) and tumorigenesis. Exp Cell Res.
368:137–146. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Thomson RB, Igarashi P, Biemesderfer D,
Kim R, Abu-Alfa A, Soleimani M and Aronson PS: Isolation and cDNA
cloning of Ksp-cadherin, a novel kidney-specific member of the
cadherin multigene family. J Biol Chem. 270:17594–17601. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Brabant G, Hoang-Vu C, Cetin Y, Dralle H,
Scheumann G, Mölne J, Hansson G, Jansson S, Ericson LE and Nilsson
M: E-cadherin: A differentiation marker in thyroid malignancies.
Cancer Res. 53:4987–4993. 1993.PubMed/NCBI
|
|
36
|
Mitselou A, Ioachim E, Peschos D,
Charalabopoulos K, Michael M, Agnantis NJ and Vougiouklakis T:
E-cadherin adhesion molecule and syndecan-1 expression in various
thyroid pathologies. Exp Oncol. 29:54–60. 2007.PubMed/NCBI
|
|
37
|
Reid BM, Permuth JB, Chen YA, Fridley BL,
Iversen ES, Chen Z, Jim H, Vierkant RA, Cunningham JM,
Barnholtz-Sloan JS, et al: Genome-wide analysis of common copy
number variation and epithelial ovarian cancer risk. Cancer
Epidemiol Biomarkers Prev. 28:1117–1126. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fragkos M, Ganier O, Coulombe P and
Méchali M: DNA replication origin activation in space and time. Nat
Rev Mol Cell Biol. 16:360–374. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ganai RA and Johansson E: DNA
replication-A matter of fidelity. Mol Cell. 62:745–755. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Burgers PMJ and Kunkel TA: Eukaryotic DNA
replication fork. Annu Rev Biochem. 86:417–438. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Syväoja J, Suomensaari S, Nishida C,
Goldsmith JS, Chui GS, Jain S and Linn S: DNA polymerases alpha,
delta, and epsilon: Three distinct enzymes from HeLa cells. Proc
Natl Acad Sci USA. 87:6664–6668. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Forsburg SL: Eukaryotic MCM proteins:
Beyond replication initiation. Microbiol Mol Biol Rev. 68:109–131.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Stoeber K, Tlsty TD, Happerfield L, Thomas
GA, Romanov S, Bobrow L, Williams ED and Williams GH: DNA
replication licensing and human cell proliferation. J Cell Sci.
114:2027–2041. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Das M, Prasad SB, Yadav SS, Govardhan HB,
Pandey LK, Singh S, Pradhan S and Narayan G: Over expression of
minichromosome maintenance genes is clinically correlated to
cervical carcinogenesis. PLoS One. 8:e696072013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kwok HF, Zhang SD, McCrudden CM, Yuen HF,
Ting KP, Wen Q, Khoo US and Chan KY: Prognostic significance of
minichromosome maintenance proteins in breast cancer. Am J Cancer
Res. 5:52–71. 2014.PubMed/NCBI
|
|
46
|
Issac MSM, Yousef E, Tahir MR and Gaboury
LA: MCM2, MCM4, and MCM6 in Breast Cancer: Clinical Utility in
Diagnosis and Prognosis. Neoplasia. 21:1015–1035. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Shinbrot E, Henninger EE, Weinhold N,
Covington KR, Göksenin AY, Schultz N, Chao H, Doddapaneni H, Muzny
DM, Gibbs RA, et al: Exonuclease mutations in DNA polymerase
epsilon reveal replication strand specific mutation patterns and
human origins of replication. Genome Res. 24:1740–1750. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Rayner E, van Gool IC, Palles C, Kearsey
SE, Bosse T, Tomlinson I and Church DN: A panoply of errors:
Polymerase proofreading domain mutations in cancer. Nat Rev Cancer.
16:71–81. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wang Y, Chen Y, Wang C, Yang M, Wang Y,
Bao L, Wang JE, Kim B, Chan KY, Xu W, et al: MIF is a 3′ flap
nuclease that facilitates DNA replication and promotes tumor
growth. Nat Commun. 12:29542021. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Preston BD, Albertson TM and Herr AJ: DNA
replication fidelity and cancer. Semin Cancer Biol. 20:281–293.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Palles C, Cazier JB, Howarth KM, Domingo
E, Jones AM, Broderick P, Kemp Z, Spain SL, Guarino E, Salguero I,
et al CORGI Consortium; WGS500 Consortium, : Germline mutations
affecting the proofreading domains of POLE and POLD1 predispose to
colorectal adenomas and carcinomas. Nat Genet. 45:136–144. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Siraj AK, Parvathareddy SK, Bu R, Iqbal K,
Siraj S, Masoodi T, Concepcion RM, Ghazwani LO, AlBadawi I,
Al-Dayel F, et al: Germline POLE and POLD1 proofreading domain
mutations in endometrial carcinoma from Middle Eastern region.
Cancer Cell Int. 19:3342019. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Nicolas E, Golemis EA and Arora S: POLD1:
Central mediator of DNA replication and repair, and implication in
cancer and other pathologies. Gene. 590:128–141. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Sanefuji K, Taketomi A, Iguchi T,
Sugimachi K, Ikegami T, Yamashita Y, Gion T, Soejima Y, Shirabe K
and Maehara Y: Significance of DNA polymerase delta catalytic
subunit p125 induced by mutant p53 in the invasive potential of
human hepatocellular carcinoma. Oncology. 79:229–237. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Sigurdson AJ, Hauptmann M, Chatterjee N,
Alexander BH, Doody MM, Rutter JL and Struewing JP: Kin-cohort
estimates for familial breast cancer risk in relation to variants
in DNA base excision repair, BRCA1 interacting and growth factor
genes. BMC Cancer. 4:92004. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Samanta D and Almo SC: Nectin family of
cell-adhesion molecules: Structural and molecular aspects of
function and specificity. Cell Mol Life Sci. 72:645–658. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Harjunpää H, Llort Asens M, Guenther C and
Fagerholm SC: Cell Adhesion Molecules and Their Roles and
Regulation in the Immune and Tumor Microenvironment. Front Immunol.
10:10782019. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Krause G, Winkler L, Mueller SL, Haseloff
RF, Piontek J and Blasig IE: Structure and function of claudins.
Biochim Biophys Acta. 1778:631–645. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Singh AB, Sharma A and Dhawan P: Claudin
family of proteins and cancer: An overview. J Oncol.
2010:5419572010. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Bhat AA, Syed N, Therachiyil L, Nisar S,
Hashem S, Macha MA, Yadav SK, Krishnankutty R, Muralitharan S,
Al-Naemi H, et al: Claudin-1, A Double-Edged Sword in Cancer. Int J
Mol Sci. 21:5692020. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Zhou B, Moodie A, Blanchard AA, Leygue E
and Myal Y: Claudin 1 in breast cancer: New insights. J Clin Med.
4:1960–1976. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Németh J, Németh Z, Tátrai P, Péter I,
Somorácz A, Szász AM, Kiss A and Schaff Z: High expression of
claudin-1 protein in papillary thyroid tumor and its regional lymph
node metastasis. Pathol Oncol Res. 16:19–27. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Hucz J, Kowalska M, Jarzab M and Wiench M:
Gene expression of metalloproteinase 11, claudin 1 and selected
adhesion related genes in papillary thyroid cancer. Endokrynol Pol.
57 (Suppl A):18–25. 2006.(In Polish). PubMed/NCBI
|
|
64
|
Fluge Ø, Bruland O, Akslen LA, Lillehaug
JR and Varhaug JE: Gene expression in poorly differentiated
papillary thyroid carcinomas. Thyroid. 16:161–175. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Li J, Chigurupati S, Agarwal R, Mughal MR,
Mattson MP, Becker KG, Wood WH III, Zhang Y and Morin PJ: Possible
angiogenic roles for claudin-4 in ovarian cancer. Cancer Biol Ther.
8:1806–1814. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Piontek A, Eichner M, Zwanziger D, Beier
LS, Protze J, Walther W, Theurer S, Schmid KW, Führer-Sakel D,
Piontek J, et al: Targeting claudin-overexpressing thyroid and lung
cancer by modified Clostridium perfringens enterotoxin. Mol Oncol.
14:261–276. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Pober JS, Gimbrone MA Jr, Lapierre LA,
Mendrick DL, Fiers W, Rothlein R and Springer TA: Overlapping
patterns of activation of human endothelial cells by interleukin 1,
tumor necrosis factor, and immune interferon. J Immunol.
137:1893–1896. 1986.PubMed/NCBI
|
|
68
|
Kotteas EA, Boulas P, Gkiozos I, Tsagkouli
S, Tsoukalas G and Syrigos KN: The intercellular cell adhesion
molecule-1 (ICAM-1) in lung cancer: Implications for disease
progression and prognosis. Anticancer Res. 34:4665–4672.
2014.PubMed/NCBI
|
|
69
|
Buitrago D, Keutgen XM, Crowley M,
Filicori F, Aldailami H, Hoda R, Liu YF, Hoda RS, Scognamiglio T,
Jin M, et al: Intercellular adhesion molecule-1 (ICAM-1) is
upregulated in aggressive papillary thyroid carcinoma. Ann Surg
Oncol. 19:973–980. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Min IM, Shevlin E, Vedvyas Y, Zaman M,
Wyrwas B, Scognamiglio T, Moore MD, Wang W, Park S, Park S, et al:
CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid
Tumors. Clin Cancer Res. 23:7569–7583. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Gray KD, McCloskey JE, Vedvyas Y, Kalloo
OR, Eshaky SE, Yang Y, Shevlin E, Zaman M, Ullmann TM, Liang H, et
al: PD1 blockade enhances ICAM1-directed CAR T therapeutic efficacy
in advanced thyroid cancer. Clin Cancer Res. 26:6003–6016. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Ohkawara B, Glinka A and Niehrs C: Rspo3
binds syndecan 4 and induces Wnt/PCP signaling via
clathrin-mediated endocytosis to promote morphogenesis. Dev Cell.
20:303–314. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Chen LL, Gao GX, Shen FX, Chen X, Gong XH
and Wu WJ: SDC4 gene silencing favors human papillary thyroid
carcinoma cell apoptosis and inhibits epithelial mesenchymal
transition via Wnt/beta-catenin pathway. Mol Cells. 41:853–867.
2018.PubMed/NCBI
|
